PLA2R1 and membranous glomerulonephritis: Membranous nephropathy (MN) is characterized by autoantibodies targeting podocyte antigens, such as Anti-phospholipase-A2 receptor (PLA2R) or Anti-Thrombospondin Type 1 (THSD7A), while 20% to 30% are secondary to immune complex deposition due to an underlying condition.[1] Therefore, clinical assessment is essential to evaluate for malignancy, infections, autoimmune conditions, or drug-related triggers.